Cytoskeletal regulatory gene expression and migratory properties of B-cell progenitors are affected by the ETV6-RUNX1 rearrangement

Molecular Cancer Research

Volumn 12, Issue 12, 2014, Pages 1796-1806

  Palmi, Chiara ^a   Fazio, Grazia ^a   Savino, Angela M ^a   Procter, Julia ^b   Howell, Louise ^b   Cazzaniga, Valeria ^a   Vieri, Margherita ^a   Longinotti, Giulia ^a   Brunati, Ilaria ^a   Andrè, Valentina ^a   Mina, Pamela Della ^a   Villa, Antonello ^a   Greaves, Mel ^b   Biondi, Andrea ^a   D'Amico, Giovanna ^a   Ford, Anthony ^b   Cazzaniga, Giovanni ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CXCR4; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN CDC42; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1; CDC42 PROTEIN, MOUSE; CXCL12 PROTEIN, MOUSE; CXCR4 PROTEIN, MOUSE; ONCOPROTEIN; TEL-AML1 FUSION PROTEIN;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; CYTOSKELETON; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE REARRANGEMENT; IN VITRO STUDY; MOUSE; MURINE MODEL; NONHUMAN; PRE B LYMPHOCYTE; REGULATOR GENE; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; CELL MOTION; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

MURINAE;

ANIMALS; CDC42 GTP-BINDING PROTEIN; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CXCL12; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYTOSKELETON; GENE EXPRESSION REGULATION; MICE; MODELS, BIOLOGICAL; ONCOGENE PROTEINS, FUSION; PRECURSOR CELLS, B-LYMPHOID; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION;

EID: 84919389976     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0056-T     Document Type: Article

References (50)

1. Romana SP, Mauchauffe M, Le Coniat M, Chumakov I, Le Paslier D, Berger R, et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 1995;85:3662-70.
2. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 1995; 92:4917-21.
3. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995;9:1985-9.
4. Zelent A, Greaves M, Enver T. Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene 2004;23:4275-83.
5. Mori H, Colman SM, Xiao Z, Ford AM, Healy LE, Donaldson C, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA 2002;99:8242-7.
6. Greaves MF, Maia AT, Wiemels JL, Ford AM. Leukemia in twins: lessons in natural history. Blood 2003;102:2321-33.
7. Tsuzuki S, Seto M, Greaves M, Enver T. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice. Proc Natl Acad Sci U S A 2004;101:8443-8.
8. Morrow M, Horton S, Kioussis D, Brady HJM, Williams O. TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity. Blood 2004;103:3890-6.
9. Fischer M, Schwieger M, Horn S, Niebuhr B, Ford A, Roscher S, et al. Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model. Oncogene 2005;24:7579-91.
10. Andreasson P, Schwaller J, Anastasiadou E, Aster J, Gilliland DG. The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo. Cancer Genetics and Cytogenetics 2001; 130:93-104.
11. Sabaawy HE, Azuma M, Embree LJ, Tsai HJ, Starost MF, Hickstein DD. TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2006;103:15166-71.
12. Ford AM, Palmi C, Bueno C, Hong D, Cardus P, Knight D, et al. The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest 2009;119:826-36.
13. Schindler JW, Van Buren D, Foudi A, Krejci O, Qin J, Orkin SH, et al. TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia. Cell Stem Cell 2009;5:43-53.
14. Diakos C, Krapf G, Gerner C, Inthal A, Lemberger C, Ban J, et al. RNAimediated silencing of TEL/AML1 reveals a heat-shock protein- and survivin-dependent mechanism for survival. Blood 2007;109:2607-10.
15. Inthal A, Krapf G, Beck D, Joas R, Kauer MO, Orel L, et al. Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia. Clin Cancer Res 2008;14:7196-204.
16. Gefen N, Binder V, Zaliova M, Linka Y, Morrow M, Novosel A, et al. Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia 2010;24:89-96.
17. Torrano V, Procter J, Cardus P, Greaves M, Ford AM. ETV6-RUNX1 promotes survival of early B lineage progenitor cells via a dysregulated erythropoietin receptor. Blood 2011;118:4910-8.
18. Patrick CW Jr, Smith TW, McIntire LV, Juneja HS. Cellular interactions among marrow stromal and normal/neoplastic pre-B- and B-lymphoblastic cells. Leuk Lymphoma 1996;22:205-19.
19. Chen YY, Malik M, Tomkowicz BE, Collman RG, Ptasznik A. BCRABL1 alters SDF-1alpha-mediated adhesive responses through the beta2 integrin LFA-1 in leukemia cells. Blood 2008;111:5182-6.
20. Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS, et al. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood 1999;94:4233-46.
21. Chang YC, Tien SC, Tien HF, Zhang H, Bokoch GM, Chang ZF. p210 (Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alphadirected migration in chronic myeloid leukemia cells. Oncogene 2009; 28:4105-15.
22. Michaud J, Simpson KM, Escher R, Buchet-Poyau K, Beissbarth T, Carmichael C, et al. Integrative analysis of RUNX1 downstream pathways and target genes. BMC Genomics 2008;9:363.
23. Wotton S, Terry A, Kilbey A, Jenkins A, Herzyk P, Cameron E, et al. Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. Oncogene 2008;27: 5856-66.
24. Char fi C, Voisin V, LevrosLC Jr, Edouard E, Rassart E. Gene profiling of Graffi murine leukemia virus-induced lymphoid leukemias: identification of leukemia markers and Fmn2 as a potential oncogene. Blood 2011;117:1899-910.
25. Vaskova M, Kovac M, Volna P, Angelisova P, Mejstrikova E, Zuna J, et al. High expression of cytoskeletal protein drebrin in TEL/AML1pos B-cell precursor acute lymphoblastic leukemia identified by a novel monoclonal antibody. Leuk Res 2011;35:1111-3.
26. Fuka G, Kauer M, Kofler R, Haas OA, Panzer-Grumayer R. The leukemia-specific fusion gene ETV6/RUNX1 perturbs distinct key biological functions primarily by gene repression. PLoS One 2011;6: e26348.
27. Fazio G, Palmi C, Rolink A, Biondi A, Cazzaniga G. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells. Cancer Res 2008;68:181-9.
28. Fazio G, Cazzaniga V, Palmi C, Galbiati M, Giordan M, Te Kronnie G, et al. PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5. Leukemia 2013;27:992-5.
29. Karasuyama H, Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol 1988;18:97-104.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8.
31. Csanaky G, Matutes E, Vass JA, Morilla R, Catovsky D. Adhesion receptors on peripheral blood leukemic B cells. A comparative study on B cell chronic lymphocytic leukemia and related lymphoma/leukemias. Leukemia 1997;11:408-15.
32. Joberty G, Perlungher RR, Macara IG. The Borgs, a new family of Cdc42 and TC10 GTPase-interacting proteins. Mol Cell Biol 1999;19: 6585-97.
33. Du Y, Bock BC, Schachter KA, Chao M, Gallo KA. Cdc42 induces activation loop phosphorylation and membrane targeting of mixed lineage kinase 3. J Biol Chem 2005;280:42984-93.
34. Kolluri R, Tolias KF, Carpenter CL, Rosen FS, Kirchhausen T. Direct interaction of the Wiskott-Aldrich syndrome protein with the GTPase Cdc42. Proc Natl Acad Sci U S A 1996;93:5615-8.
35. Funasaka K, Ito S, Hasegawa H, Goldberg GS, Hirooka Y, Goto H, et al. Cas utilizes Nck2 to activate Cdc42 and regulate cell polarization during cell migration in response to wound healing. FEBS J 2010;277: 3502-13.
36. Miyamoto Y, Yamauchi J, Mizuno N, Itoh H. The adaptor protein Nck1 mediates endothelin A receptor-regulated cell migration through the Cdc42-dependent c-Jun N-terminal kinase pathway. J Biol Chem 2004;279:34336-42.
37. Sipes NS, Feng Y, Guo F, Lee HO, Chou FS, Cheng J, et al. Cdc42 regulates extracellular matrix remodeling in three dimensions. J Biol Chem 2011;286:36469-77.
38. Haddad E, Zugaza JL, Louache F, Debili N, Crouin C, Schwarz K, et al. The interaction between Cdc42 and WASP is required for SDF-1-induced T-lymphocyte chemotaxis. Blood 2001;97:33-38.
39. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009;113:6085-93.
40. Flaishon L, Becker-Herman S, Hart G, Levo Y, Kuziel WA, Shachar I. Expression of the chemokine receptor CCR2 on immature B cells negatively regulates their cytoskeletal rearrangement and migration. Blood 2004;104:933-41.
41. Flaishon L, Hart G, Zelman E, Moussion C, Grabovsky V, Lapidot Tal G, et al. Anti-inflammatory effects of an inflammatory chemokine: CCL2 inhibits lymphocyte homing by modulation of CCL21-triggered integ-rin-mediated adhesions. Blood 2008;112:5016-25.
42. Fukuda S, Broxmeyer HE, Pelus LM. Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha (CXCL12)/CXCR4 axis. Blood 2005;105:3117-26.
43. Tu S, Wu WJ, Wang J, Cerione RA. Epidermal growth factor-dependent regulation of Cdc42 is mediated by the Src tyrosine kinase. J Biol Chem 2003;278:49293-300.
44. Raaijmakers MH. Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system. Haematologica 2011 Jul;96:1041-8.
45. Guo ZG, Cai SX, Fang R, Chen HY, Du J, Tan Y, et al. The synergistic effects of CXCR4 and EGFR on promoting EGF-mediated metastasis in ovarian cancer cells (vol 60, pg 1, 2007). Colloid Surface B 2008; 60:1-6.
46. Mosadegh B, Saadi W, Wang SJ, Jeon NL. Epidermal growth factor promotes breast cancer cell chemotaxis in CXCL12 gradients. Biotechnol Bioeng 2008;100:1205-13.
47. Borowitz MJ, Rubnitz J, Nash M, Pullen DJ, Camitta B. Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood Bprecursor ALL: a Pediatric Oncology Group Study. Leukemia 1998;12: 1764-70.
48. Leung KT, Chan KYY, Ng PC, Lau TZ, Chiu WM, Tsang KS, et al. The tetraspanin CD9 regulates migration, adhesion, and homing of human cord blood Cd34 + hematopoietic stem and progenitor cells. Blood 2011;117:1840-50.
49. Sattler M, Salgia R. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev 1997;8:63-79.
50. Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S, et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008;319:336-9.